NeurAxis (NRXS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting is scheduled for June 10, 2026, with voting on key proposals including director elections, auditor ratification, amendments to the 2022 Omnibus Securities and Incentive Plan, and approval of the 2025 Employee Stock Purchase Plan.
Shareholders of record as of April 14, 2026, are eligible to vote, with both Common Stock and Series B Preferred Stock voting as a single class.
Voting can be conducted online, by phone, mail, or in person, with detailed instructions provided.
Voting matters and shareholder proposals
Proposals include electing six directors, ratifying the appointment of Rosenberg Rich Baker Berman, P.A. as auditor, amending the 2022 Plan to increase authorized shares and extend the evergreen provision, approving the 2025 Employee Stock Purchase Plan, and authorizing adjournment if needed.
The board recommends voting FOR all proposals.
Shareholder proposals for the 2027 annual meeting must be submitted by April 10, 2027.
Board of directors and corporate governance
The board consists of six members, with four qualifying as independent under SEC and NYSE American rules.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined responsibilities and independent membership.
Directors who are employees receive no additional compensation; non-employee directors are compensated per policy.
The company has adopted a Code of Conduct and Insider Trading Policy, and maintains D&O liability insurance.
Latest events from NeurAxis
- Q1 2026 revenue up 80% with margin gains, FDA clearances, and ongoing going concern risks.NRXS
Q1 202612 May 2026 - Key votes include director elections, auditor ratification, and major equity plan amendments.NRXS
Proxy filing29 Apr 2026 - FDA-cleared neuromodulation device targets $22B+ GI market with strong clinical and payer support.NRXS
Corporate presentation19 Apr 2026 - FY2025 revenue rose 33% to $3.6M, with strong margins and expanded market access.NRXS
Q4 202519 Mar 2026 - Insurance coverage gains and new product launches set stage for growth and profitability in 2025.NRXS
Q2 20241 Feb 2026 - Strong clinical data and insurance gains position the company for rapid growth and profitability.NRXS
Lytham Partners Fall 2024 Investor Conference19 Jan 2026 - New CPT code and expanded coverage drive growth for a non-drug GI therapy with strong margins.NRXS
2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026 - Q3 revenue up 40%, net loss down 80%, with major insurance and FDA milestones achieved.NRXS
Q3 202415 Jan 2026 - Rapid insurance expansion and CPT code milestone drive strong revenue growth and future outlook.NRXS
Lytham Partners 2025 Investor Healthcare Summit10 Jan 2026